Skip to content

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525862-23-00
Enrollment
39
Registered
2026-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson disease

Brief summary

The primary endpoint is the Patient Global Impression-Change (PGI-C) score completed by the patient compared between botulinum toxin injection and placebo injection at 6weeks after the injection on treatment-refractory resting tremor of the upper limb, in patients with PD

Detailed description

1. The effect of botulinum toxin: a. on resting tremor will be measured by: i. The change score on the CGI-C (Clinician Global Impression-Change) investigator scale, at six weeks post-injection; ° The delta of the severity scores on the CGI-S (Clinician Global Impression-Severity) investigator scale between injection and six weeks post-injection; ° The delta of the score of item 3.17 (amplitude) on the MDS-UPDRS III investigator scale between injection and six weeks post-injection; ii. The de, The effect of botulinum toxin on the patient's experience will be measured by: a. The delta of the patient's quality of life score on the PDQ-39 self-questionnaire between the injection and six weeks post-injection b. The delta of the activities of daily living score using the MDS-UPDRS part two scale between injection and six weeks post-injection, Safety of use will be measured by: a. The delta of the measurement in Newtons of the manual dynamometer, for the treated hand, between the injection and six weeks post-injection The delta of the scores for severity of muscle weakness in the treated hand, using the PGI-S scale (Patient Global Impression-Severity) completed by the patient between the injection and six weeks post-injection Collection of adverse events throughout the duration of the study

Interventions

DRUGpoudre pour solution injectable
DRUGEntonox 50%/50% gaz medicinal comprimat
DRUGNaCl

Sponsors

Centre Hospitalier Universitaire De Toulouse
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the Patient Global Impression-Change (PGI-C) score completed by the patient compared between botulinum toxin injection and placebo injection at 6weeks after the injection on treatment-refractory resting tremor of the upper limb, in patients with PD

Secondary

MeasureTime frame
1. The effect of botulinum toxin: a. on resting tremor will be measured by: i. The change score on the CGI-C (Clinician Global Impression-Change) investigator scale, at six weeks post-injection; ° The delta of the severity scores on the CGI-S (Clinician Global Impression-Severity) investigator scale between injection and six weeks post-injection; ° The delta of the score of item 3.17 (amplitude) on the MDS-UPDRS III investigator scale between injection and six weeks post-injection; ii. The de, The effect of botulinum toxin on the patient's experience will be measured by: a. The delta of the patient's quality of life score on the PDQ-39 self-questionnaire between the injection and six weeks post-injection b. The delta of the activities of daily living score using the MDS-UPDRS part two scale between injection and six weeks post-injection, Safety of use will be measured by: a. The delta of the measurement in Newtons of the manual dynamometer, for the treated hand, between the injectio

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 25, 2026